Literature DB >> 17328979

Economic evaluation of services for a National Health scheme: the case for a fairness-based framework.

Jeff Richardson1, John McKie.   

Abstract

In this paper we argue that the usual framework for evaluating health services may need modification in the context of a National Health Scheme (NHS). Some costs and benefits may need to be ignored or discounted, others included at face value, and some transfer payments included in the decision algorithm. In contrast with the standard framework, we argue that economic evaluation in the context of an NHS should focus on 'social transfers' between taxpayers and beneficiaries, and that the nature and scope of these transfers is determined by the level of social generosity. Some of the implications of a modified framework are illustrated with a re-examination of (i) costs and transfer payments, (ii) unrelated future costs, (iii) moral hazard, and (iv) the rule that marginal costs should equal marginal benefits. We argue that an explicitly 'fairness-based' framework is needed for the evaluation of services in an NHS. In contrast, the usual welfare economic theoretic framework facilitates the sidelining of issues of fairness.

Mesh:

Year:  2007        PMID: 17328979     DOI: 10.1016/j.jhealeco.2006.11.004

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  5 in total

1.  Severity as an independent determinant of the social value of a health service.

Authors:  Jeff R J Richardson; John McKie; Stuart J Peacock; Angelo Iezzi
Journal:  Eur J Health Econ       Date:  2010-05-09

2.  [The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].

Authors:  M Schlander; G-E Trott; O Schwarz
Journal:  Nervenarzt       Date:  2010-03       Impact factor: 1.214

3.  Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement.

Authors:  Michael Schlander; Silvio Garattini; Peter Kolominsky-Rabas; Erik Nord; Ulf Persson; Maarten Postma; Jeff Richardson; Steven Simoens; Oriol de Solà-Morales; Keith Tolley; Mondher Toumi
Journal:  J Mark Access Health Policy       Date:  2016-10-27

4.  Determining Value in Health Technology Assessment: Stay the Course or Tack Away?

Authors:  J Jaime Caro; John E Brazier; Jonathan Karnon; Peter Kolominsky-Rabas; Alistair J McGuire; Erik Nord; Michael Schlander
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

5.  How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment.

Authors:  Michael Schlander; Karla Hernandez-Villafuerte; Chih-Yuan Cheng; Jorge Mestre-Ferrandiz; Michael Baumann
Journal:  Pharmacoeconomics       Date:  2021-08-09       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.